Cytel Inc. is the leading provider of clinical trial design services and specialized statistical applications for the biopharmaceutical, medical device, academic and government research markets. Cytel’s East® system is used by biostatisticians and clinicians at hundreds at commercial sites, throughout academia and by regulators to design, simulate and monitor group sequential and adaptive clinical trials. Cytel provides trial sponsors with innovative tools, training and consultation to increase process efficiencies and reduce development costs.

Products & Services

Cytel Inc. has a 20-plus year track record as the premier provider of software and services for the design and analysis of clinical trials. Cytel provides the applications, training and consultative services to clinical trial sponsors seeking to increase trial efficiencies and reduce drug development costs in phase 1, 2 and 3 studies. Cytel’s East® system is used by hundreds of biostatisticians and clinicians throughout industry, academia and at every major branch of the FDA to design, simulate and monitor group sequential and adaptive clinical trials. Over 10,000 customers also use Cytel’s award-winning StatXact®, and LogXact® applications for exact statistical inference.

The company’s Clinical Research Services division, established in 2005, is now a key contributor to Cytel's growth. This unit offers the following major service lines: clinical program design, trial implementation support, clinical data submission, and statistical methods collaborative development.

Cytel’s products and services are sold worldwide through a direct sales and business development team coupled with an inside sales force, global distributor network, Internet sales and OEM arrangements. The company forecasts continued strong demand for both products and services.

With groundbreaking solutions, highly-respected founders and advisory board members, a top-notch management team and a customer base that includes most of the world’s leading biopharmaceutical companies, Cytel is well positioned for long-term growth and market leadership.